Zions Bancorporation N.A. Has $69,000 Position in Becton, Dickinson and Company (NYSE:BDX)

Zions Bancorporation N.A. trimmed its position in Becton, Dickinson and Company (NYSE:BDX) by 17.2% during the third quarter, HoldingsChannel.com reports. The fund owned 285 shares of the medical instruments supplier’s stock after selling 59 shares during the period. Zions Bancorporation N.A.’s holdings in Becton, Dickinson and Company were worth $69,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Schrum Private Wealth Management LLC boosted its position in shares of Becton, Dickinson and Company by 100.0% during the third quarter. Schrum Private Wealth Management LLC now owns 2,700 shares of the medical instruments supplier’s stock worth $651,000 after purchasing an additional 1,350 shares in the last quarter. Aptus Capital Advisors LLC raised its stake in Becton, Dickinson and Company by 37.6% during the 3rd quarter. Aptus Capital Advisors LLC now owns 3,673 shares of the medical instruments supplier’s stock worth $886,000 after buying an additional 1,004 shares during the period. Aigen Investment Management LP lifted its holdings in Becton, Dickinson and Company by 7.8% during the third quarter. Aigen Investment Management LP now owns 2,362 shares of the medical instruments supplier’s stock worth $569,000 after acquiring an additional 170 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. grew its stake in Becton, Dickinson and Company by 1.7% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 668,792 shares of the medical instruments supplier’s stock valued at $161,246,000 after acquiring an additional 11,276 shares during the period. Finally, GSA Capital Partners LLP bought a new stake in shares of Becton, Dickinson and Company in the third quarter worth about $458,000. Institutional investors own 86.97% of the company’s stock.

Analyst Ratings Changes

BDX has been the topic of several recent analyst reports. Evercore ISI lifted their price objective on Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and lifted their price target for the company from $255.00 to $275.00 in a research note on Tuesday, October 1st. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Raymond James cut their price objective on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research report on Friday, August 2nd. Finally, Stifel Nicolaus increased their target price on Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a report on Friday, July 26th. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $283.00.

Becton, Dickinson and Company Trading Down 0.9 %

Becton, Dickinson and Company stock opened at $225.15 on Friday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.17 and a quick ratio of 0.74. The firm has a 50-day moving average of $236.44 and a 200-day moving average of $235.05. The company has a market cap of $65.08 billion, a price-to-earnings ratio of 38.15, a P/E/G ratio of 1.72 and a beta of 0.43. Becton, Dickinson and Company has a one year low of $218.75 and a one year high of $249.89.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, beating analysts’ consensus estimates of $3.77 by $0.04. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The firm had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. During the same period last year, the company earned $3.42 earnings per share. The business’s revenue was up 6.9% compared to the same quarter last year. On average, equities analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 31st. Shareholders of record on Monday, December 9th will be given a dividend of $1.04 per share. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. This represents a $4.16 annualized dividend and a yield of 1.85%. The ex-dividend date is Monday, December 9th. Becton, Dickinson and Company’s dividend payout ratio is 63.97%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.